Derniers articles

Prognostic value of CD4+ T lymphopenia in non-small cell lung Cancer

AbstractBackground: There is a paucity of data regarding the prognostic influence of peripheral blood CD4+ T...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : BMC cancer

Metastatic renal cell cancer and first-line combinations: for which patients? (focus on tolerance and health-related quality of life)

AbstractUntil recently, the first-line treatments used in metastatic renal cell carcinoma were based on first-generation...

Posté par :
Nom de la revue : Bulletin du cancer

Metastatic renal cell cancer and first-line combinations: for which patients? (focus on tolerance and health-related quality of life)

AbstractUntil recently, the first-line treatments used in metastatic renal cell carcinoma were based on first-generation...

Posté par :
Nom de la revue : Bulletin du cancer

Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR)

AbstractBackground: Histological characteristics at the invasive front may reflect tumor aggressiveness;...

Posté par : Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Nom de la revue : Annals of oncology

Result of one-year, prospective follow-up of intensive care unit survivors after SARS-CoV-2 pneumonia

AbstractIntroduction: Survivors of viral ARDS are at risk of long-term physical, functional and neuropsychological...

Posté par : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY, Dr. Sophie PAGET-BAILLY
Nom de la revue : Annals of Intensive Care

Interest of the Addition of Taxanes to Standard Treatment in First-Line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients

AbstractBackground: Studies have reported a beneficial role of the addition of trastuzumab to platin-5-FU based...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Frontiers in oncology

Is it safe to perform an anastomosis for rectal cancer after prostate cancer? A multicentre study of 126 patients from the GRECCAR group

AbstractAim: To determine the safety of performing an anastomosis after rectal cancer (RC) resection in patients...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Colorectal Dis

Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies

AbstractBackground: Squamous cell carcinoma of the anus (SCCA) is a rare disease often diagnosed at a localised...

Posté par : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Eur J Cancer

Immune microenvironment in patients with mismatch-repair-proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study

AbstractIn the era of immune checkpoint inhibitors, understanding the metastatic microenvironment of proficient mismatch...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Mol Oncol

Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin

AbstractPurpose: Early-onset (EO) colorectal cancer (CRC, age < 50 years) incidence is increasing. Decisions on...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : J Clin Oncol

%TTD and %TUDD: New SAS macro programs to calculate the survival data of the time to deterioration for patient-reported outcomes data in oncology

AbstractBackground and objective: Longitudinal analysis of patient-reported outcome (PRO) data remains challenging,...

Posté par : Mr. Antoine FALCOZ
Nom de la revue : Comput Methods Programs Biomed

Impact of Immunoscore on the Management of Stage II Colon Cancer Patients: A Physician Survey

AbstractBackground: Adjuvant chemotherapy use in stage II colon cancer is controversial. Current prognostic risk...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Cancers (Basel)

HPV16 Load Is a Potential Biomarker to Predict Risk of High-Grade Cervical Lesions in High-Risk HPV-Infected Women: A Large Longitudinal French Hospital-Based Cohort Study

AbstractHigh-risk HPV (hrHPV) testing has been implemented as a primary screening tool for cervical cancer in numerous...

Posté par : Mme. Julie HENRIQUES, Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY, Dr. Sophie PAGET-BAILLY
Nom de la revue : Cancers (Basel)

Metastatic colorectal carcinoma with signet-ring cells: Clinical, histological and molecular description from an Association des Gastro-Entérologues Oncologues (AGEO) French multicenter retrospective cohort

AbstractBackground: Metastatic signet-ring cell colorectal carcinoma is rare. We analyzed its clinicopathological...

Posté par : , Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Dig Liver Dis

Impact of open-label versus blinded study design on patient-reported outcomes data in randomized clinical trials of immunotherapy in advanced or metastatic cancer patients: a systematic review

AbstractAim: A systematic literature review of immuno-oncology trials was conducted to assess the potential impact of...

Posté par : Mr. Antoine FALCOZ,
Nom de la revue : Qual Life Res

Prognostic value and relation with adjuvant treatment duration of ctDNA in stage III colon cancer: a post-hoc analysis of the PRODIGE-GERCOR IDEA-France trial

AbstractPurpose: Circulating tumor DNA (ctDNA) has been suggested as a major prognostic factor in resected stage...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Clin Cancer Res .

Additive Value of Preoperative Sarcopenia and Lymphopenia for Prognosis Prediction in Localized Pancreatic Ductal Adenocarcinoma

AbstractBackground: Surgical resection with adjuvant chemotherapy is the only treatment that can provide long term...

Posté par : Dr. Dewi VERNEREY, ,
Nom de la revue : Front Oncol

Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment

AbstractCirculating cell-free DNA (cfDNA) contains circulating tumor DNA (ctDNA), which can be obtained from serial...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Mol Oncol .

Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer

AbstractBackground: Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis have changed the first-line...

Posté par : Dr. Sophie PAGET-BAILLY
Nom de la revue : Cochrane Database Syst Rev

Palliative care in day-hospital for advanced cancer patients: a study protocol for a multicentre randomized controlled trial

AbstractBackground: Team-based and timely integrated palliative care is a gold standard of care in oncology, but...

Posté par :
Nom de la revue : BMC Palliat Care .

Derniers articles

Prognostic value of CD4+ T lymphopenia in non-small cell lung Cancer

Metastatic renal cell cancer and first-line combinations: for which patients? (focus on tolerance and health-related quality of life)

Metastatic renal cell cancer and first-line combinations: for which patients? (focus on tolerance and health-related quality of life)

Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR)

Result of one-year, prospective follow-up of intensive care unit survivors after SARS-CoV-2 pneumonia

Interest of the Addition of Taxanes to Standard Treatment in First-Line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients

Is it safe to perform an anastomosis for rectal cancer after prostate cancer? A multicentre study of 126 patients from the GRECCAR group

Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies

Immune microenvironment in patients with mismatch-repair-proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study

Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin

%TTD and %TUDD: New SAS macro programs to calculate the survival data of the time to deterioration for patient-reported outcomes data in oncology

Impact of Immunoscore on the Management of Stage II Colon Cancer Patients: A Physician Survey

HPV16 Load Is a Potential Biomarker to Predict Risk of High-Grade Cervical Lesions in High-Risk HPV-Infected Women: A Large Longitudinal French Hospital-Based Cohort Study

Metastatic colorectal carcinoma with signet-ring cells: Clinical, histological and molecular description from an Association des Gastro-Entérologues Oncologues (AGEO) French multicenter retrospective cohort

Impact of open-label versus blinded study design on patient-reported outcomes data in randomized clinical trials of immunotherapy in advanced or metastatic cancer patients: a systematic review

Prognostic value and relation with adjuvant treatment duration of ctDNA in stage III colon cancer: a post-hoc analysis of the PRODIGE-GERCOR IDEA-France trial

Additive Value of Preoperative Sarcopenia and Lymphopenia for Prognosis Prediction in Localized Pancreatic Ductal Adenocarcinoma

Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment

Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer

Palliative care in day-hospital for advanced cancer patients: a study protocol for a multicentre randomized controlled trial

 Archives

 Contributor

↑